Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics-Reference-Cited by-同舟云学术

Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics

Published:2009-06-08 Issue:7 Volume:5 Page:803-812
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Gibiansky Leonid,Gibiansky Ekaterina

Publisher

Informa Healthcare

Subject

Pharmacology,Toxicology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/17425250902992901

Reference39 articles.

1. Kuester K, Kloft C. Pharmacokinetics of monoclonal antibodies. In: Meibohm B, editor, pharmacokinetics and pharmacodynamics of biotech drugs: principles and case studies in drug development. WILEY-VCH Verlag GmbH & Co. KGaA,Weinheim 2006. p. 45-91

2. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

3. Pharmacologic target-mediated drug disposition

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A model‐based approach using GSK3772847, an anti‐interleukin‐33 receptor monoclonal antibody, as a showcase to predict SC administration PK and free target dynamics based on PK and total target measurements after IV administration;CPT: Pharmacometrics & Systems Pharmacology;2024-09-11

2. Validity conditions of approximations for a target-mediated drug disposition model: A novel first-order approximation and its comparison to other approximations;PLOS Computational Biology;2024-04-24

3. Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer;Expert Opinion on Drug Metabolism & Toxicology;2022-11-02

4. Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review;Pharmaceutics;2022-09-30

5. Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease;CPT: Pharmacometrics & Systems Pharmacology;2022-09-27